1. Home
  2. TBLA vs NVAX Comparison

TBLA vs NVAX Comparison

Compare TBLA & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taboola.com Ltd.

TBLA

Taboola.com Ltd.

HOLD

Current Price

$4.95

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$7.49

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBLA
NVAX
Founded
2007
1987
Country
United States
United States
Employees
2000
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
TBLA
NVAX
Price
$4.95
$7.49
Analyst Decision
Strong Buy
Hold
Analyst Count
4
9
Target Price
$5.00
$11.33
AVG Volume (30 Days)
2.7M
3.4M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
309.76
EPS
N/A
N/A
Revenue
N/A
$1,123,479,000.00
Revenue This Year
$7.63
N/A
Revenue Next Year
$5.25
N/A
P/E Ratio
$42.36
N/A
Revenue Growth
N/A
64.69
52 Week Low
$2.84
$6.20
52 Week High
$5.71
$11.85

Technical Indicators

Market Signals
Indicator
TBLA
NVAX
Relative Strength Index (RSI) 46.31 33.90
Support Level $3.94 $6.38
Resistance Level $5.18 $10.10
Average True Range (ATR) 0.18 0.35
MACD -0.09 -0.12
Stochastic Oscillator 24.46 8.93

Price Performance

Historical Comparison
TBLA
NVAX

About TBLA Taboola.com Ltd.

Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: